Onar names Kelly Anderson interim CFO, Howard Palefsky to chair Audit Committee
Bitget2026/10/08 12:03Onar named Kelly Anderson interim CFO effective Oct. 1 to lead Advertise Purple financial integration and Nasdaq listing preparation. Anderson has 25+ years in senior finance, has overseen 400+ acquisitions, was CFO at T3 Motion and Mavenlink. She previously served as chief accounting officer at Fisker Automotive, is a CPA, founded CXO Executive Solutions. Anderson stepped down from the board and as Audit Committee chair; director Howard D. Palefsky took over as chair. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onar Holding Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610080800PRIMZONEFULLFEED9841382) on October 08, 2026, and is solely responsible for the information contained therein.
- Onar named Kelly Anderson interim CFO effective Oct. 1 to lead Advertise Purple financial integration and Nasdaq listing preparation.
- Anderson has 25+ years in senior finance, has overseen 400+ acquisitions, was CFO at T3 Motion and Mavenlink.
- She previously served as chief accounting officer at Fisker Automotive, is a CPA, founded CXO Executive Solutions.
- Anderson stepped down from the board and as Audit Committee chair; director Howard D. Palefsky took over as chair.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
